Adaptive Biotechnologies Corp. (ADPT)
28.35
+0.98
(+3.58%)
USD |
NASDAQ |
Oct 02, 16:00
28.34
-0.02
(-0.05%)
After-Hours: 20:00
Adaptive Biotechnologies Enterprise Value : 4.583B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 4.583B |
| October 01, 2026 | 4.427B |
| September 30, 2026 | 4.671B |
| September 29, 2026 | 4.650B |
| September 28, 2026 | 4.609B |
| September 25, 2026 | 4.755B |
| September 24, 2026 | 4.777B |
| September 23, 2026 | 4.510B |
| September 22, 2026 | 4.537B |
| September 21, 2026 | 4.505B |
| September 18, 2026 | 4.625B |
| September 17, 2026 | 4.615B |
| September 16, 2026 | 4.475B |
| September 15, 2026 | 4.318B |
| September 14, 2026 | 4.015B |
| September 11, 2026 | 3.923B |
| September 10, 2026 | 3.928B |
| September 09, 2026 | 3.958B |
| September 08, 2026 | 3.946B |
| September 04, 2026 | 3.936B |
| September 03, 2026 | 3.982B |
| September 02, 2026 | 3.996B |
| September 01, 2026 | 3.946B |
| August 31, 2026 | 4.038B |
| August 28, 2026 | 4.081B |
| Date | Value |
|---|---|
| August 27, 2026 | 4.280B |
| August 26, 2026 | 4.235B |
| August 25, 2026 | 4.249B |
| August 24, 2026 | 4.138B |
| August 21, 2026 | 4.208B |
| August 20, 2026 | 4.120B |
| August 19, 2026 | 4.128B |
| August 18, 2026 | 3.980B |
| August 17, 2026 | 4.014B |
| August 14, 2026 | 4.009B |
| August 13, 2026 | 3.965B |
| August 12, 2026 | 4.090B |
| August 11, 2026 | 4.113B |
| August 10, 2026 | 4.122B |
| August 07, 2026 | 4.039B |
| August 06, 2026 | 3.828B |
| August 05, 2026 | 3.987B |
| August 04, 2026 | 3.979B |
| August 03, 2026 | 3.750B |
| July 31, 2026 | 3.664B |
| July 30, 2026 | 3.920B |
| July 29, 2026 | 3.662B |
| July 28, 2026 | 3.656B |
| July 27, 2026 | 3.659B |
| July 24, 2026 | 3.616B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Personalis, Inc. | 1.557B |
| 10X Genomics, Inc. | 11.71B |
| Alamar Biosciences, Inc. (California) | 2.186B |
| Champions Oncology, Inc. | 75.94M |
| Medpace Holdings, Inc. | 16.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.94M |
| Revenue (Quarterly) | 71.55M |
| Total Expenses (Quarterly) | 111.34M |
| EPS Diluted (Quarterly) | -0.2489 |
| Gross Profit Margin (Quarterly) | 70.15% |
| Profit Margin (Quarterly) | -55.82% |
| Earnings Yield | -1.44% |
| Normalized Earnings Yield | -1.055 |